I (Ingle and Kuizenga, 1945; Ingle, 1946; Pabst and others, 1947) . Moreover, data are rapidly accumulating from clinical investigations which indicate that hydrocortisone is, milligram for milligram, distinctly more powerful than cortisone in anti-inflammatory and anti-allergic activity, and that it may often be employed more advantageously as a therapeutic agent.
Preparations of Hydrocortisone Two forms of hydrocortisone are available commercially: the pure hormone-hydrocortisone (free alcohol) -herein referred to as hydrocortisone; and an esterhydrocortisone acetate. The two compounds must be carefully distinguished as they differ decidedly in solubility and absorption, and in therapeutic effectiveness when given orally. Hydrocortisone is much more soluble in various media and, when administered by mouth, Figure.
-Chemical structure of (a) hydrocortisone and (b) cortisone. (Boland, 1952a (Boland, 1952a, b, c) . These studies disclosed was the fact that one or more abnormal signs either that the maintenance requirements for hydrocorti-lessened substantially or disappeared in 22 of the sone were uniformly less, and it was estimated that, 31 patients (71 per cent.). Certain individual the hormone was at least 50 per cent. more effective, reactions tended toward correction more than others:
ORAL HYDROCORTISONE IN RHEUMATOID ARTHRITIS nervous symptoms disappeared or were reduced in thirteen of fifteen patients, oedema in nine of fifteen patients, and moon facies and supraclavicular fat pads in nine of 23 patients; but generalized obesity was corrected in only two of nine patients, and signs such as hypertrichosis (twelve patients) and irregular glycosuria (two patients) were not changed during the periods of observation.
Patients treated initially with Hydrocortisone. J In a preliminary study, ten patients with rheumatoid arthritis were given hydrocortisone as initial treatment in dosages similar to those customarily employed for cortisone acetate (Boland and Headley, 1952) . During these short-term investigations it was noted that the general pattern of improvement corresponded closely to that which results from cortisone acetate. With the same milligram doses, however, the onset of relief from hydrocortisone was faster and more striking, subsequent improvement progressed more quickly, and elevated erythrocyte sedimentation rates diminished more rapidly and regularly. These observations suggested that smaller doses of hydrocortisone given at the beginning of treatment might accomplish satisfactory suppression of the disease.
Subsequently, long-term studies have been instituted, using hydrocortisone as the only form of therapy. To date sixteen patients have received the hormone continuously for more than 12 weeks, some for as long as 30 weeks. The same general plan of treatment as that used for cortisone acetate was followed. This involved three stages:
(1) initial suppressive doses, (2) gradual dosage reduction, (3) maintenance therapy.
The smallest daily amount of hormone capable of controlling the disease manifestations adequately, but not necessarily completely, was considered the optimal maintenance dose for long-term therapy. Because hydrocortisone is rapidly absorbed and its effects are rapidly dissipated, the total daily dose was J divided routinely into four parts, taken at mealtimes and at bedtime.
The initial suppressive doses employed for these sixteen patients were substantially less than those ordinarily prescribed for cortisone acetate IAdequate improvement (marked or very marked)| was maintained in fifteen of the sixteen patients, anc so far only three have developed untoward signs of hormone excess, mild in each instance. These data, as well as the deductions derived from them, must, however, be considered as preliminary and tentative, as this part of the study now includes only a few patients followed for a relatively short time; and it may be anticipated that improvement may deteriorate in some patients when treatment is continued for longer periods. Summary Hydrocortisone (Compound F) was administered orally to two series of patients with rheumatoid arthritis. One group (44 cases) was given hydrocortisone after periods ranging from 10 to 138 weeks (average 60) during which they had received cortisone acetate (Compound E). A second group (sixteen cases) was treated with hydrocortisone from the beginning.
These clinical investigations led to the following conclusions:
(1) The antirheumatic activity of hydrocortisone is greater than that of cortisone or cortisone acetate when the substances are given orally in equivalent doses.
(2) The daily doses required for initial suppression of the disease and for maintenance of satisfactory improvement are appreciably smaller with hydrocortisone. Milligram for milligram, the antirheumatic potency of hydrocortisone may be estimated as at least 50 Ces recherches cliniques menerent aux conclusions suivantes:
(1) L'action anti-rhumatismale de la hydrocortisone est plus forte que celle de la cortisone ou de l'acetate de cortisone, pourvu qu'on administre ces substances par voie buccale et a des doses equivalentes.
(2) Les doses quotidiennes necessaires pour obtenir la suppression initiale de la maladie et pour maintenir une amelioration satisfaisante sont appreciablement plus faibles pour la hydrocortisone. Milligramme pour milligramme, le pouvoir antirhumatismal de la hydrocortisone peut etre estime comme etant au moins 50% superieur A celui de la cortisone ou de l'acetate de cortisone et A peu pres 100% superieur A celui de l'acetate de hydrocortisone.
(3) La dissociation entre l'effet anti-inflammatoire et les autres effets endocrines semble plus accentuee avec la hydrocortisone qu'avec l'acetate de cortisone, de maniere que des doses plus faibles mais aussi efficaces de hydrocortisone sont suffisantes pour eviter ou bien controler plus facilement les manifestation nefastes de l'exces d'hormone.
(4) En tant qu'agent th6rapeutique exigeant l'administration interne prolongee dans les maladies chroniques sensibles A son action, telles que l'arthrite rhumatismale, la hydrocortisone semble 1'emporter sur l'acetate de cortisone.
Hidrocortisona por via oral en la artritis reumatoide SUMARIO Se administr6 hidrocortisona (Compuesto F) por via oral a dos grupos de enfermos con artritis reumatoide. Cuarenta y cuatro enfermos previamente tratados con acetato de cortisona (Compuesto E) durante periodos de 10 a 138 semanas (un promedio de 60) formaron un grupo; dieciseis casos sin tratamiento hormonal previo formaron el otro.
Estas investigaciones clinicas dieron lugar a las conclusiones siguientes:
(1) La accion antirreumatica de la hidrocortisona es mas fuerte que la de la cortisona o del acetato de cortisona cuando se administra estas substancias por via oral en dosis equivalentes.
(2) Las dosis diarias de hidrocortisona necesarias para obtener la supresi6n inicial de la enfermedad y para mantener una mejoria satisfactoria son apreciablemente mas pequefias. Miligramo por miligramo, el poder antirreumatico de la hidrocortisona parece superar al de la cortisona o del acetato de cortisona de un 50% al menos y al del acetato de hidrocortisona de cerca de un 100%.
(3) La disociaci6n entre el efecto anti-inflamatorio y los demas efectos endocrinos parece mAs acentuada con la hidrocortisona que con el acetato de cortisona; con dosis mAs pequefias pero igualmente eficaces de hidrocortisona se puede evitar o controlar mas facilmente la manifestaciones indeseables del exceso hormonal.
(4) Como agente precisando una administraci6n interna prolongada en enfermedades cr6nicas que responden a su acci6n, como en la artritis reumatoide, la hidrocortisona parece terapeuticamente superior al acetato de cortisona.
